GGrantIndex
Sort

30,917 grants matching tumor microenvironment

Multidimensional analyses to improve PSMA-RPT efficacy in mCRPC

$584,235
Johannes Czernin · University Of California Los Angeles · R01 · FY2025 · CA

Engineering immunotherapeutic probiotics to mitigate irAE

$584,146
Tal Danino · Columbia Univ New York Morningside · U01 · FY2022 · CA

Patient-specific, high-sensitivity spectral CT for assessment of pancreatic cancer

$583,894
Peter B Noã‹l · University Of Pennsylvania · R01 · FY2024 · EB

Intratumor co-delivery of DNA and RNA to relieve cancer pain

$583,847
Brian L Schmidt · New York University · R01 · FY2025 · DE

Intratumor co-delivery of DNA and RNA to relieve cancer pain

$583,847
Brian L Schmidt · New York University · R01 · FY2021 · DE

Intratumor co-delivery of DNA and RNA to relieve cancer pain

$583,847
Brian L Schmidt · New York University · R01 · FY2023 · DE

Project 1: Multi-scale modeling of adaptive drug resistance in BRAF-mutant melanoma

$583,801
Peter Karl Sorger · Harvard Medical School · U54 · FY2018 · CA

Temporal analysis of the GBM tumor microenvironment during myeloid cell activating therapy

$583,794
Ralph Weissleder · Massachusetts General Hospital · R01 · FY2025 · CA

Glycosylation and Immune Evasion in Urologic Tumors

$583,786
Sharon Pitteri · Stanford University · U01 · FY2023 · CA

The Role of TIMPs in Cell Growth, Tumor Progression and Metastasis

$583,776
William Stetler-Stevenson · Division Of Clinical Sciences - Nci · ZIA · FY2014 · CA

Dissecting the role of hypoxia in T cell differentiation in cancer

$583,740
Greg M. Delgoffe · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · CA

Therapeutic Targeting Mitochondrial C1 Metabolism

$583,716
Larry H. Matherly · Wayne State University · R01 · FY2024 · CA

Tech Core 2

$583,706
Denis Wirtz · Johns Hopkins University · U54 · FY2022 · CA

Development of Novel Spontaneous HPV Cervicovaginal Carcinoma Models for Cancer Immunotherapy

$583,657
T.-C. Wu · Johns Hopkins University · R01 · FY2020 · CA

Mechanisms of treatment failure in chimeric antigen receptor T cell therapy

$583,532
Brian Till · Fred Hutchinson Cancer Research Center · R01 · FY2019 · CA

Focused ultrasound pre-conditioning for augmented nanoparticle penetration in infiltrative gliomas

$583,441
Richard J Price · University Of Virginia · R01 · FY2023 · EB

Exploring DNA damage response pathways as targets for cancer therapy

$583,430
Junjie Chen · University Of Tx Md Anderson Can Ctr · R35 · FY2022 · CA

Metformin for chemoprevention of lung cancer in obese subjects at high risk

$583,338
Saikrishna Yendamuri · Roswell Park Cancer Institute Corp · R01 · FY2025 · CA

Development of Novel Spontaneous HPV Cervicovaginal Carcinoma Models for Cancer Immunotherapy

$583,258
T.-C. Wu · Johns Hopkins University · R01 · FY2021 · CA

Novel Hyperpolarized MR Markers of Advanced Prostate Cancer Therapy

$583,254
John Kurhanewicz · University Of California, San Francisco · R01 · FY2014 · CA

Overcoming the immune-suppressive tumor microenvironment through in situ vaccination nanotechnology.

$583,253
Nicole Franziska Steinmetz · University Of California, San Diego · U01 · FY2021 · CA

The Role of Kaiso as a predictive breast cancer biomarker in Africa and across the African Diaspora

$583,243
Kevin L. Gardner · Columbia University Health Sciences · R01 · FY2025 · CA

Protein kinase C signaling in prostate cancer health disparities

$583,194
Marcelo Gabriel Kazanietz · University Of Miami School Of Medicine · R01 · FY2025 · CA

Validation of a novel 3D culture platform for TNBC treatment selection

$583,104
Kyuson Yun · Methodist Hospital Research Institute · R01 · FY2024 · CA

Immune Therapy for Brain Metastasis

$583,091
Lucia Beatrice Jilaveanu · Yale University · R01 · FY2023 · CA